EU Approves Bristol Myers Squibb's Opdivo for Frontline Advanced Hodgkin Lymphoma
BMY sits 34% above its 52-week low of $42.52 on elevated volume (2.4× avg).
Summary
Bristol Myers Squibb's Opdivo, in combination with AVD, has received expanded EU label approval for frontline advanced classical Hodgkin Lymphoma. This regulatory win broadens the market for a key oncology drug, allowing it to be used earlier in treatment for a serious condition. This follows a series of positive drug development announcements for the company, including recent trial results for mezigdomide and Camzyos.
At the time of this announcement, BMY was trading at $57.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $116.8B. The 52-week trading range was $42.52 to $62.89. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.